くすりのしおり

Injection
Published: 2/2017

The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
Brand name :
ERBITUX Injection 100mg
 Active ingredient:
Cetuximab(genetical recombination)
 Dosage form:
injection
 Print on wrapping:

Effects of this medicine

This medicine inhibits factors related to cancer cell growth (EGFR: epidermal growth factor receptor) to suppress cancer cell growth.
It is usually used to treat EGFR-positive large intestine cancer (colorectal cancer) or head and neck cancer.

Before using this medicine, be sure to tell your doctor and pharmacist

  • If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
    If you have previously experienced infusion reaction such as respiratory distress, hives, reduction in blood pressure or loss of consciousness after infusion of any medicines.
    If you have heart disease (heart failure, arrhythmia, etc.) or have received treatment due to heart disease.
    If you have a history of interstitial lung disease.
    If you have an allergic history to beef/pork or a history of tick bites.
  • If you are pregnant or breastfeeding.
  • If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)

Dosing schedule (How to take this medicine)

  • Your dosing schedule prescribed by your doctor is ((        to be written by a healthcare professional))
  • In general, for adults, administer by intravenous infusion once a week.
  • Ask your doctor about the treatment span.
  • You will be administered medicines to prevent infusion reaction (antihistamine agent, etc.) before drip infusion of this medicine.

Precautions while taking this medicine

  • Keep your skin clean and moisturize the skin to prevent development/aggravation of skin symptoms after injection.
  • When you take a bath/shower, use lukewarm water. Avoid taking a long bath/shower. After a bath/shower, moisturize your skin as soon and much as possible. Wash your body softly with mild materials. Do not rub your skin hardly.
  • Wear loose clothes and shoes not to tighten your body. Take adequate measures to protect your skin from ultraviolet rays when you go outside. Avoid skin irritation as much as possible.

Possible adverse reactions to this medicine

The most commonly reported adverse reactions include acne, dry skin, rash, diarrhea, pruritus, loss of appetite, nausea, fatigue, mucosal inflammation, acneform dermatitis, perionychia and stomatitis. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
  • anaphylaxis symptoms such as acute respiratory distress, hives, reduction in blood pressure and loss of consciousness [infusion reaction]
  • acneform rash, dry skin, skin inflammation [severe skin symptoms]
  • cough, shortness of breath, fever, dullness [interstitial lung disease]
  • chest pain, chest distress (symptoms such as angina and myocardial infration) [heart failure]
  • abdominal pain, severe diarrhea, dehydration [severe diarrhea]
  • breathing difficulty, chest distress, pain when pushing the calf [thromboembolism]
  • symptoms such as pneumonia and sepsis [infection]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.

Storage conditions and other information

  • Bovine-derived materials are used during the manufacturing process of this medicine. Although no transmission of transmissible spongiform encephalopathy (TSE) to humans caused by administration of this medicine has been reported to date, the theoretical risk of transmission of TSE through this medicine cannot be completely ruled out.

For healthcare professional use only : Day Month Year

For further information, talk to your doctor or pharmacist.

Keywords Search

 

 

 

 

Advanced Search

Browse by drug name A-Z
Browse by drug name A-Z